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Abstract
Background: This study aimed to investigate genetic polymorphisms of CYP2D6 among healthy Uygur individuals.
Genetic polymorphisms of CYP2D6 could greatly affect CYP2D6 activity and lead to differences among individuals
in drug efficacy or side effects. To investigate genetic polymorphisms of CYP2D6 in the Uygur population, we
directly sequenced the whole gene in 96 unrelated, healthy Uygur volunteers from the Xinjiang Uygur Autonomous
Region and screened for genetic variants in the promoter, intron, exons, and 3’UTR.
Results: We detected 62 genetic polymorphisms of CYP2D6, 16 of which were novel SNP with three novel
non-synonymous mutations detected for the first time. The allelic frequencies of CYP2D6*1, *10, *39, and *48
were 0.542, 0.156, 0.068, 0.229, and 0.073, respectively. The frequency of CYP2D6*1/*10 which decreased
CYP2D6 enzyme activity was 31.3 %.
Conclusions: Our results provided basic information about CYP2D6 polymorphisms, suggested that the enzymatic
activities of CYP2D6 might be different within the Uygur ethnic group, and provide a basis for safer drug administration
and better therapeutic treatment of Uygur individuals.
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Background
The CYP superfamily is one of the most important enzyme
systems involved in the biotransformation of many en-
dogenous and exogenous substances. Cytochrome P450
(CYP450) enzymes are essential for the metabolism of
many medications. This class has more than 50 enzymes,
among them CYP2D6 is one of the most significant en-
zymes [1]. The enzyme accounts for only a small percent-
age of all hepatic P450s, but its role in drug metabolism is
extensively higher than its relative content [2]. CYP2D6 is
an important polymorphic phase-I drug-metabolism en-
zyme and plays an important role in the metabolism of a
variety of drugs and environmental compounds [3]. It is an
important member of the cytochrome oxidase P450
enzyme system, and polymorphisms in CYP450 enzymes
are responsible for observed variation in drug responses
among patients of different ethnic origins. The CYP2D6
gene located at chromosome 22q 13.2 is one of the most
polymorphic CYP450 genes. It contains nine exons and
eight introns, has a full-length base coding sequence of
1491 bp, expresses about 497 amino acids, and is involved
in the metabolism of 20–25 % of clinical prescription drugs
[4]. For instance, Debrisoquine, Antidepressants,Tricyclic
antidepressants, Beta-blockers et al. It has a high degree of
genetic variation. To date, more than 300 variants of the
CYP2D6 gene have been identified (http://www.cypalleles.-
ki.se), although multiple allele identified no function [5].
CYP2D6*3, CYP2D6*4, CYP2D6*5, and CYP2D6*6 are re-
ported to be associated with decreased enzymatic activity,
CYP2D6 * 4 is the most common mutants in Caucasians.
About 5 % to 10 % and 1 % are slow metabolism in Cauca-
sians and Asians respectively. Three common mutant al-
leles related with reduced catalytic activity, CYP2D6 * 10
were found mainly in Asians, CYP2D6*17 were found
mainly in African. CYP2D6 * 41 were found in African and
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Caucasians. In addition to fast metabolizers, more than
5 % of Caucasians are classified as ultra-fast metabolizers,
Because of multiple copies in the CYP2D6 gene which en-
hances the ability of metabolism [6]. For example, seven
percent of Caucasoid and two to seven percent of Negroid
individuals are poor metabolizers of drugs dependent on
CYP2D6, which metabolizes many beta blockers, antide-
pressants, opioids, and other compounds [7]. The Uygur
population, comprising 10,069,346 individuals (The Sixth
National Census), lives almost entirely within the Xinjiang
Uygur Autonomous Region, Northwestern frontier area of
China, represents a typical admixture population with a
genetic background of Caucasians (40 %) and East Asians
(60 %) [8, 9]. At present, there is no comprehensive system
for the study of CYP2D6 polymorphisms in the Uygur
population of China. So to establish a database of CYP2C9
allele frequencies for the healthy Uygurs, which would be
useful for personalized medicine, we decided to systematic-
ally screen the polymorphisms of the CYP2C9 gene and
compared their allelic frequencies with previous data of
other ethnic groups. We hoping to identify characteristics
of the genetic polymorphisms of CYP2D6 and provide rea-
sonable recommendations pertaining to the safer adminis-




We recruited a random sample of 96 healthy, unrelated
Uygur individuals (48 males and 48 females) between
November 2014 and January 2015 from the Tibet Na-
tionality College in Xianyang for genetic polymorphism
research. All of the chosen subjects were volunteers liv-
ing in the Xinjiang Uygur Autonomous Region of China
and had at least three generations of Uygur paternal an-
cestry. Our research adopted strict recruitment and ex-
clusion rules. We excluded individuals with chronic
diseases, conditions involving vital organs (lung, heart,
kidney, brain, and liver), and several metabolic endo-
crinological, metabolic, and nutritional diseases. The
purpose of the exclusion procedures was to minimize
the known environmental and therapeutic factors that
influence genetic variation in the genes of interest.
We informed all of the participants of the experimental
procedures and the purpose of the study. The Human Re-
search Committee for the Approval of Research Involving
Human Subjects at the Xizang Mingzu University approved
the use of human tissue in this study. We also obtained
signed, informed consent from each study participant.
PCR and DNA sequencing
Genomic DNA was extracted from 300 μl peripheral
blood using a GoldMagMini Whole Blood Genomic DNA
Purification Kit (GoldMag Ltd). The purity of the ex-
tracted DNA reached above 99 %. Our PCR primers,
which were described in a previous study, were designed
to amplify 2000 bp of the 5’ flanking regions, all exons,
and all introns of the CYP2D6 gene [10]. The 10 μl PCR
system contained 5 μl Hotstar Taq Master Mix, 1 μl gen-
omic DNA (20 ng/μl), 0.5 μl each primer pair (5 μM), and
3 μl deionized water. The PCR reaction conditions were
as follows: the thermal profile consisted of denaturation at
95 °C for 15 min, followed by 35 cycles of denaturation at
95 °C for 30 s, 60 °C for 30 s, and extension at 72 °C for
1 min, followed by a final extension at 72 °C for 3 min and
subsequent storage at 4 °C. We detected the PCR prod-
ucts by agarose gel electrophoresis and directly sequenced
them using an ABI Prism BigDye Terminator Cycle Se-
quencing Kit version 3.1 on an ABI Prism 3100 sequencer
(Applied Biosystems).
Data analysis
The CYP2D6 variants were named based on the nucleo-
tide reference sequence AY545216 (http:www.cypalleles.-
ki.se/) and the protein reference sequence P10635. The
allelic and genotypic frequencies were calculated by a stat-
istical method. Comparisons of allelic frequencies among
different geographic populations or other ethnic popula-
tions were done using chi-squared tests with the signifi-
cance level set at 0.05. Our study used Haploview 4.1 to
assess linkage disequilibrium (LD) and Hardy-Weinberg
equilibrium for each genetic variant [11]. We constructed
haplotypes from selected tag SNPs and derived the haplo-
type frequencies for the Uygur population.
Functional prediction
To analyze variants in the exon regions of CYP2D6, our
study adopted the online tool PolyPhen2 (http://genet-
ics.bwh.harvard.edu/pph2/) and SIFT (http://sift.bii.a-
star.edu.sg/) to predict the protein function of missense
mutations, which could change the function of the cyto-
chrome P450 enzyme. Each variant was evaluated based
on the impact of protein function. The PolyPhen2 output
was divided into five categories: probably benign (0.000–
0.999), borderline (1.000–1.249), potentially damaging
(1.250–1.449), possibly damaging (1.500–1.999) and prob-
ably damaging (≥2.000). The protein function predicted by
two aspects included HumVar and HumDiv.. The SIFT
output was divided into four categories: tolerant (0.201–
1.00), borderline (0.101–0.20), potentially intolerant
(0.051–0.10) and intolerant (0.00–0.05).
Results
Genetic variants
We successfully identified CYP2D6 polymorphisms in 96
healthy, unrelated Uygur volunteers from the Tibet Na-
tionality College. We identified a total of 62 CYP2D6
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Table 1 The frequencies and positions of CYP2D6 genetic variants in the Uygur population
SNP Allele Position Nucleotide change Frequency Region Amino-acid effect
rs1080989 −1000 R(G > A) 46.67 % Promoter No translated
rs28624811 −740 Y(C > T) 59.38 % Promoter No translated
rs28633410 −678 R(G > A) 59.38 % Promoter No translated
rs74966855 −498 M(C > A) 5.21 % Promoter No translated
rs1080992 −365 R(G > A) 4.17 % Promoter No translated
/ −334 S(G > C) 1.04 % Promoter No translated
rs34167214 −331 K(T > G) 1.04 % Promoter No translated
rs35534760 −328 Y(C > T) 1.04 % Promoter No translated
−327 R(A > G) 1.04 % Promoter No translated
/ −321 S(C > G) 1.04 % Promoter No translated
/ −320 R(A > G) 1.04 % Promoter No translated
/ −203 Y(C > T) 1.04 % Promoter No translated
/ −202 R(G > A) 1.04 % Promoter No translated
/ −97 R(G > A) 1.04 % Promoter No translated
rs769258 31 R(G > A) 3.16 % Exon1 Val11Met
rs1065852 CYP2D6*10 100 Y(C > T) 45.26 % Exon1 Pro34Ser
rs146558635 123 M(C > A) 1.05 % Exon1 Pro41 = SM
rs1080995 214 S(G > C) 59.38 % Intron 1 No translated
rs1080996 221 M(C > A) 59.38 % Intron 1 No translated
rs74644586 223 S(C > G) 59.38 % Intron 1 No translated
rs76312385 227 Y(T > C) 59.38 % Intron 1 No translated
rs75276289 232 S(G > C) 61.46 % Intron 1 No translated
rs28695233 233 M(A > C) 45.83 % Intron 1 No translated
rs56011157 245 R(A > G) 45.83 % Intron 1 No translated
/ 254 K(G > T) 1.04 % Intron 1 No translated
rs29001678 270 Y(C > T) 2.08 % Intron 1 No translated
rs28371699 310 K(G > T) 84.38 % Intron 1 No translated
/ 317 R(A > G) 1.05 % Intron 1 No translated
/ 323 R(G > A) 1.05 % Intron 1 No translated
rs28371701 745 S(C > G) 57.29 % Intron 1 No translated
rs71328650 842 K(T > G) 57.29 % Intron 1 No translated
rs28371703 CYP2D6*48 973 M(C > A) 14.58 % Exon 2 Leu91Met
rs28371704 983 R(A > G) 14.58 % Exon 2 His94Arg
rs28371705 996 S(C > G) 16.67 % Exon 2 Thr98 = SM
rs1081003 CYP2D6*10 1038 Y(C > T) 31.25 % Exon 2 Phe112 = SM
rs368389952 1070 R(G > A) 1.04 % Intron 2 No translated
rs1081004 1169 R(G > A) 4.17 % Intron 2 No translated
rs1058164 CYP2D6*10 CYP2D6 *39 1662 S(G > C) 77.08 % Exon 3 Val136 = SM
novel 1673 R(G > A) 1.04 % Exon 3 Arg140His
novel 2467 Y(T > C) 7.29 % Exon 5 Leu231Pro
novel 2471 Y(T > C) 9.38 % Exon 5 His232 = SM
rs28371718 2576 M(C > A) 9.38 % Exon 5 Pro267 = SM
novel 2607 R(G > A) 100.00 % Exon 5 Glu278Lys
rs201830078 2611 W(T > A) 9.38 % Exon 5 Met279Lys
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polymorphisms in the current Uygur population which
contained 16 novel found SNP. Among 62 Uygur CYP2D6
polymorphisms, there were 19 amino-acid effects which
contained nine synonymous mutations and ten non-
synonymous mutations, and five of which were novel. The
synonymous mutations included 2471 T > C and 3273G >
C, and the non-synonymous mutations included 1673G >
A, 2467 T > C and 2607G >A (Table 1).
Allelic frequencies and genotypic frequencies
We identified five CYP2D6 alleles in the Uygur popula-
tion. The CYP2D6*1 allele had the highest frequency
(47.4 %) and represented the wild-type CYP2D6 allele,
which was followed by the CYP2D6*39 allele (22.9 %)
and the CYP2D6*10 allele (15.6 %). The other two al-
leles, CYP2D6*27 and *48, were relatively rare. The
CYP2D6 allelic frequencies within the Uygur population
are shown in Table 2.
We also detected five CYP2D6 genotypes, with fre-
quencies ranging from 5.2 to 35.4 % in the Uygur
population. The heterozygous genotype *1/*10 (31.3 %)
led to a decrease in enzyme activity, while the other four
genotypes, including *1/*27 (13.5 %), *1/*39 (35.4 %), *1/
*48 (14.6 %), and the rare homozygous *39/*39 (5.2 %),
did not affect the enzyme activity. According to the
Haploview analysis, all of the allelic and genotypic fre-
quencies fit Hardy-Weinberg equilibrium. The CYP2D6
genotypic frequencies are shown in Table 3.
We further compared the CYP2D6 allelic frequencies
between the Uygur population and other ethnic popula-
tions from various countries. The frequencies of
CYP2D6*10, *27, and *39 in the Uygur population were
different from those in the other ethnic groups (Table 4).
Linkage disequilibrium analysis
We adopted the Haploview software to perform LD
analysis with confidence intervals to define blocks. LD
is the population-genomic feature used in genetic as-
sociation studies to find the location of variants that
predispose individuals to genetic diseases [12]. The D’
Table 1 The frequencies and positions of CYP2D6 genetic variants in the Uygur population (Continued)
rs76015180 2662 R(G > A) 1.09 % Intron 5 No translated
rs28371722 2664 R(G > A) 6.52 % Intron 5 No translated
rs187203531 2721 S(G > C) 1.09 % Intron 5 No translated
rs28371726 3255 Y(T > C) 1.04 % Exon 7 His361 = SM
novel 3273 S(G > C) 1.04 % Exon 7 Giy367 = SM
/ 3350 K(G > T) 1.04 % Intron 7 No translated
rs1985842 3385 M(C > A) 58.33 % Intron 7 No translated
rs28578778 3394 Y(T > C) 3.13 % Intron 7 No translated
rs28371729 3436 M(C > A) 2.08 % Intron 7 No translated
rs2004511 3583 R(A > G) 44.79 % Intron 7 No translated
rs28371730 3585 R(G > A) 59.38 % Intron 7 No translated
rs28371731 3791 Y(C > T) 59.38 % Intron 7 No translated
rs28371732 3829 R(G > A) 1.04 % Exon 8 Ser401 = SM
rs769157652 CYP2D6*27 3854 R(G > A) 13.54 % Exon 8 Glu410Lys
rs1135840 CYP2D6*10 CYP2D6 *39 4181 S(G > C) 100.00 % Exon 9 Ser486Thr
/ 4375 Y(C > T) 1.04 % 3’UTR No translated
rs116390392 4482 R(G > A) 59.38 % 3’UTR No translated
rsr35028622 4723 K(T > G) 61.40 % 3’UTR No translated
The position is according to the reference sequence AY545216 in Genbank; Not translated: this SNP has no effect on the protein sequence; UTR means untranslated
region; SM means synonymous mutation
Table 2 Allelic frequencies of CYP2D6 in the Uygur population
Allele Total (n = 192) Phenotype Frequency (%)
*1 91 Normal 47.4
*10 30 Decreased 15.6
*27 13 Normal 6.8
*39 44 Normal 22.9
*48 14 Normal 7.3
Table 3 Genotypes of CYP2D6 in the Uygur population
Genotype Total (n = 96) Phenotype Frequency (%)
*1/*10 30 Decreased 31.3
*1/*27 13 Normal 13.5
*1/*39 34 Normal 35.4
*1/*48 14 Normal 14.6
*39/*39 5 Normal 5.2
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value indicated the extent of LD between these SNPs
which shown in Fig. 1. We identified two LD blocks
from our 62 Uygur polymorphisms. The first block
included two very tightly correlated markers: 842 T >
G and 745C > G. The second block had a very strong
linkage among 310G > T, 245A > G, 233A > C, 232G >
C, 227 T > C, 223C > G, 221C > A, 214G > C, 100C >
T,−678G > A and−740C > T.
Non-synonymous mutation effects
The functional consequence of the novel non-
synonymous mutations be predicted by computationally
construct the structure of mutant protein in Fig. 2. We
used PolyPhen-2 and SIFT to predict the function of
CYP2D6 which carried the ten different non-synonymous
mutations. First, we verified CYP2D6*10 (100C > T) is the
mutant with possibly damaging the enzyme activity and
CYP2D6*48 (973C > A) is another. Then we predicted the
protein function of 3 novel amino-acid change and found
1673G >A, 2467 T > C and 2607G >A is benign to the
protein function. From the result of SIFT, we found that
the results is not consistent with PolyPhen-2’. The results
of SIFT shown in Table 5 and Fig. 3 shown the predicted
results from PolyPhen-2.
Discussion
The CYP2D6 gene has been considered very difficult for
genotypic analysis, because of its numerous polymor-
phisms including SNPs, gene deletions, and duplications.
To date, multifarious studies have analyzed CYP2D6
genetic polymorphisms. Baclig et al. found that the al-
lelic frequencies of CYP2D6*10 among healthy Filipino
volunteers were similar to those among other Asians but
markedly different from those among Caucasian popula-
tions [13]. We determined that CYP2D6*10, the most
Table 4 CYP2D6 allelic frequencies in the Uygur population
Population Total number CYP2D6 frequency (%) Reference
*1 *10 *27 *39
Uygur 96 47.4 15.6 6.8 22.9
UAE 151 39.1 3.3** 0.7** 4.0** [28]
Korean 400 33.25** 45.0** 0.38** 0.63** [29]
Japanese 206 43.0 38.1** 0.2** 0.3** [30]
Brazilian 873 39.9 2.05** 0 0.8** [31]
Chinese
Han
400 24.65** 52.53** 0 0 [10]
Caucasian 330 35.5* 2.7** 0 0 [32]
Spanish 105 31* 1.9** 0 0 [33]
Austrian 93 34.9 4.3** 0 0 [34]
Sardinian 250 31.4** 5.4** 0 0 [35]
Note: **p < 0.01; *p < 0.05; the p value means the comparison of the allelic
frequencies between the Uygur population and other populations
Fig. 1 Linkage disequilibrium analysis of CYP2D6 genetic polymorphisms. Strong LD is displayed by bright red (very strong: LOD > 2, D’ = 1) or pink red
(moderately strong: LOD > 2, D’ < 1), intermediate LD is displayed by blue (LOD < 2, D’ = 1), and absence of LD is displayed by white (LOD < 2, D’ < 1)
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prevalent allele reported in the Asian population, had a
frequency of only 15.6 % among Uygur individuals. Zuo
et al. found that the frequency of the CYP2D6*10 allele
was not significantly different among the Han, Mongo-
lian, or Hui populations; although the Uighur population
showed significantly lower frequencies of that allele
compared with the other three populations [14]. Several
drugs, such as hydrocodone, are metabolized by cyto-
chrome 450 enzymes [15], so we recommended that the
dosage of that drug for Uygur individuals should be less
than that used for members of the other three
populations.
There were marked differences in the CYP2D6 al-
lelic frequencies among populations with different
continental origins. Some alleles were observed at
high frequencies in different populations, such as
CYP2D6*4 in Europeans and CYP2D6*17 in Africans
[16, 17]. For the analysis of the genetic variants of
CYP2D6 in the Uygur population, there were 19 mu-
tations, comprising nine synonymous mutations and
ten missense mutations. Six novel missense mutations
were located at the transcription site and were
predicted to result in a loss of enzyme function. Only
one novel mutation was located in the 3’UTR and
was therefore not translated, and we did not find any
mutations in the promoter region. The CYP2D6*27
allelic frequency was 6.8 % in the Uygur population;
its isoforms all showed active codeine metabolism
and dextromethorphan demethylation [18]. We also
found a high frequency of CYP2D6*39 (22.9 %) in the
Uygur population, which was different from that in
the other ethnic groups and had not been previously
described in the Uygur population. The CYP2D6*39
allele was previously reported to be common in Asian
populations and to possibly decrease the expression
level of the CYP2D6 protein; however, that allele
could not transform the protein function [19].
To date, more than 50 clinically important drug
substrates of CYP2D6 have been reported [20], in-
cluding codeine [17], dextromethorphan [21], cyclo-
phosphamide [22], tamoxifen [23], and ethylmorphine.
There has been a lack of research to provide informa-
tion regarding the influence of CYP2D6*10 on the
metabolic activity of CYP2D6 in the Uygur population
Fig. 2 Predicted computationally construct the structure of mutant protein. a Crystal Structure of Human Cytochrome P450 2D6. b CYP2D6*10
Table 5 Results of SIFT predictions of non-synonymous SNPs
SNP Substitution dbSNP Score Prediction
31G > A Val11Met rs769258 0.12 TOLERATED
100C > T Pro34Ser rs1065852 0.00 AFFECT PROTEIN FUNTION
973C > A Leu91Met rs28371703 0.01 AFFECT PROTEIN FUNTION
983A > G His94Arg rs28371704 0.35 TOLERATED
1673G > A Arg140His novel 0.00 AFFECT PROTEIN FUNTION
2467 T > C Leu231Pro novel 0.11 TOLERATED
2607G > A Glu278Lys novel 0.06 TOLERATED
2611 T > A Met279Lys rs201830078 0.00 AFFECT PROTEIN FUNTION
3854G > A Glu410Lys rs769157652 0.14 TOLERATED
4181G > C Ser486Thr rs1135840 0.37 TOLERATED
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[24]. Hamzeiy et al. [25] determined that CYP2D6*10
occurred more frequently in Iran (9 %) than in the
UAE (3.3 %). Our study provides new data on
CYP2D6 gene polymorphisms in the Uygur popula-
tion and compares the frequencies of polymorphisms
between the Uygur population and other ethnic popu-
lations. The differences in allelic frequencies indicate
that the genetic composition also varies between the
different geographical populations. That variation
could contribute significantly toward a better under-
standing of CYP2D6 polymorphisms and to the devel-
opment of a database for personalized medicine in
the Uygur population. Britzi et al. [26] found a sig-
nificant difference in the distribution of the metabolic
ratio of the “extensive metabolizer” phenotype among
Ethiopian, Russian, and Yemenite populations.
We also investigated the haplotype and LD pattern
construction of the CYP2D6 gene in the Uygur popu-
lation. The LD provided a basic profile of the gen-
omic structure of CYP2D6 in the Uygur population.
Our study analyzed the pattern of LD in CYP2D6
among the Uygur and identified two blocks. We
chose to deselect the loci that did not fit Hardy-
Weinberg equilibrium to ensure that our further
analyses produced reliable results. In order to see the
differences in the LD structure, we constructed the
haplotypes from the tag SNPs, so the haplotype struc-
ture and distributions were different in different pop-
ulations. The combined genotypic effects of some
decreased-function variants would result in inactive
enzymes. Combinations of different polymorphisms
might produce markedly different results in terms of
CYP2D6 activity.
There are some limitations in our study must be
noted. The sample size of this study is relatively
small. The number of patients in several genotypic
groups was small when the samples were divided into
different groups according to the genotype, which
could influence the study results. However, the
current study possessing enough power.
Fig. 3 Predicted protein function of all the CYP2D6 nonsynonymous mutations
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Overall, we determined that about 30 % of Uygur
individuals had genotypes associated with decreased
enzyme activity, while about 70 % of the people in
our research had genotypes associated with normal
enzyme activity. A previous study found some rela-
tionships among haplotypes and certain diseases, drug
clearance rates, and adverse drug reactions, involving
several joint mutation sites that reduced the functions
of the enzyme [27]. Different polymorphic sites and
interactions led to significant differences in enzyme
activity, and haplotype analysis was more beneficial to
the identification of metabolic phenotypes.
Conclusion
In summary, our research systematically analyzed the
variants of CYP2D6 by directly sequencing that gene
in members of the Uygur population and comparing
the results with those from other ethnic populations
around the world. Our work offers some useful infor-
mation for the establishment of a database of
CYP2D6 genetic polymorphisms in the Uygur popula-
tion, which would provide a theoretical basis for indi-
vidualized medical treatment and drug genomics
studies. Next, we will concentrate on identifying
CYP2D6 variants in a larger sample size of Uygur in-
dividuals in order to benefit the advancement of per-
sonalized medicine.
Abbreviations
CYP: Cytochrome P450; LD: Linkage disequilibrium.
Acknowledgments
This work was funded by the Major science and technology research projects
of Xizang (Tibet) Autonomous Region (2015XZ01G23) and National Natural
Science Foundation of China (No. 81560516)
Availability of supporting data
Other information is provided as supplementary files.
Authors’ contributions
Xue He and Na He carried out the molecular genetic studies. Lisong Ren
participated in the sequence alignment and drafted the manuscript. Yongri
Ouyang participated in the sequence alignment. Tianbo Jin, Ning Zhang and
Yini Ma participated in the design of the study and performed the statistical
analysis. Tianbo Jin and Longli Kang conceived of the study. Dongya Yuan
helped to draft the manuscript. All authors read and approved the final
manuscript.
Competing interests




1Key Laboratory for Basic life science Research of Tibet autonomous region
School of Medicine, Xizang Mingzu University, Xianyang, Shaanxi 712082,
China. 2Key laboratory for molecular genetic mechanisms and intervention
research on high altitude disease of Tibet autonomous region, School of
Medicine, Xizang Mingzu University, Xianyang, Shaanxi 712082, China.
3National Engineering Research Center for Miniaturized Detection Systems,
Xi’an, Shaanxi 710069, China. 4School of Life Sciences, Northwest University,
Xi’an, Shaanxi 710069, China.
Received: 6 September 2015 Accepted: 11 May 2016
References
1. Wilkinson GR. Drug metabolism and variability among patients in drug
response. N Engl J Med. 2005;352(21):2211–21.
2. Slaughter RL, Edwards DJ. Recent advances: the cytochrome P450 enzymes.
Ann Pharmacother. 1995;29(6):619–24.
3. Ji L, Pan S, Wu J, Marti-Jaun J, Hersberger M. Genetic polymorphisms of
CYP2D6 in Chinese mainland. Chin Med J. 2002;115(12):1780–4.
4. Koski A, Ojanperä I, Sistonen J, Vuori E, Sajantila A. A fatal doxepin poisoning
associated with a defective CYP2D6 genotype. Am J Forensic Med Pathol.
2007;28(3):259–61.
5. Sosa-Macías M, LLerena A. Cytochrome P450 genetic polymorphisms of
Mexican indigenous populations. Drug Metabol Drug Interact. 2013;28(4):
193–208.
6. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of
cytochrome P450 polymorphisms on drug therapies: pharmacogenetic,
pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007;116(3):496–526.
7. Kamal NNSBNM, Lim TS, Tye GJ, Ismail R, Choong YS. The Effect of CYP2B6,
CYP2D6, and CYP3A4 Alleles on Methadone Binding: A Molecular Docking
Study. Am J Chem Soc. 2013;2013:1–7.
8. Xu S, Huang W, Qian J, Jin L. Analysis of genomic admixture in Uyghur and
its implication in mapping strategy. Am J Hum Genet. 2008;82(4):883–94.
9. Yao Y-G, Kong Q-P, Wang C-Y, Zhu C-L, Zhang Y-P. Different matrilineal
contributions to genetic structure of ethnic groups in the silk road region in
china. Mol Biol Evol. 2004;21(12):2265–80.
10. Jin T-B, Ma L-F, Zhang J-Y, Yuan D-Y, Sun Q, Zong T-Y, Geng T-T, Cui Y-L, Kang
L-L, Chen C. Polymorphisms and phenotypic analysis of cytochrome P450 2D6
in the Tibetan population. Gene. 2013;527(1):360–5.
11. Barrett J, Fry B, Maller J, Daly M. Haploview: analysis and visualization of LD
and haplotype maps. Bioinformatics. 2005;21(2):263–5.
12. Zondervan KT, Cardon LR. Designing candidate gene and genome-wide
case–control association studies. Nat Protoc. 2007;2(10):2492–501.
13. Baclig MO, Predicala RZ, Mapua CA, Lozano-Kühne JP, Daroy M, Natividad
FF, Javier FO. Allelic and genotype frequencies of catechol-O-
methyltransferase (Val158Met) and CYP2D6* 10 (Pro34Ser) single nucleotide
polymorphisms in the Philippines. IntJ Mol Epidemiol Genet. 2011;3(2):115–21.
14. Zuo J, Xia D, Jia L, Guo T. Genetic polymorphisms of drug-metabolizing
phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur,
Hui and Mongolian Chinese populations. Die Pharmazie-An Int J Pharm Sci
Res. 2012;67(7):639–44.
15. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee K-H, Skaar T, Storniolo AM, Li L,
Araba A. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism
during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005;97(1):30–9.
16. Zhou S. Polymorphism of human cytochrome P450 2D6 and its clinica l
significance: part II. Clin Pharmacokinet. 2009;48(12):761–804.
17. Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE,
Haidar CE, Shen DD, Callaghan JT, Sadhasivam S. Clinical Pharmacogenetics
Implementation Consortium guidelines for cytochrome P450 2D6 genotype
and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014;95(4):376–82.
18. Zhang W-Y, Tu Y-B, Haining RL, Yu A-M. Expression and functional analysis
of CYP2D6. 24, CYP2D6. 26, CYP2D6. 27, and CYP2D7 isozymes. Drug Metab
Dispos. 2009;37(1):1–4.
19. Saruwatari J, Nakashima H, Tsuchimine S, Nishimura M, Ogusu N, Yasui-Furukori
N. Possible impact of the CYP2D6* 10 polymorphism on the nonlinear
pharmacokinetic parameter estimates of paroxetine in Japanese patients with
major depressive disorders. Pharm Pers Med. 2014;7:121.
20. Ota T, Kamada Y, Hayashida M, Iwao-Koizumi K, Murata S, Kinoshita K.
Combination analysis in genetic polymorphisms of drug-metabolizing
enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the
Japanese population. Int J Med Sci. 2014;12(1):78–82.
21. Wang D, Poi MJ, Sun X, Gaedigk A, Leeder JS, Sadee W. Common CYP2D6
polymorphisms affecting alternative splicing and transcription: long-range
haplotypes with two regulatory variants modulate CYP2D6 activity. Hum
Mol Genet. 2014;23(1):268–78.
22. Gor PP, Su HI, Gray RJ, Gimotty PA, Horn M, Aplenc R, Vaughan WP, Tallman
MS, Rebbeck TR, DeMichele A. Research article Cyclophosphamide-
metabolizing enzyme polymorphisms and survival outcomes after adjuvant
chemotherapy for node-positive breast cancer: a retrospective cohort study.
Breast Cancer. 2010;6:8.
He et al. BMC Genomics  (2016) 17:409 Page 8 of 9
23. Nakamura Y, Ratain MJ, Cox NJ, Mcleod HL, Kroetz DL, Flockhart DA. Re:
CYP2D6 genotype and tamoxifen response in postmenopausal women with
endocrine-responsive breast cancer: the Breast International Group 1–98
trial. J Natl Cancer Inst. 2012;104(16):1264.
24. Lee S-J, Lee SS, Jung H-J, Kim H-S, Park S-J, Yeo C-W, Shin J-G.
Discovery of novel functional variants and extensive evaluation of
CYP2D6 genetic polymorphisms in Koreans. Drug Metab Dispos. 2009;
37(7):1464–70.
25. Kouhi H, Hamzeiy H, Barar J, Asadi M, Omidi Y. Frequency of five important
CYP2D6 alleles within an Iranian population (Eastern Azerbaijan). Genet Test
Mol Biomarkers. 2009;13(5):665–70.
26. Britzi M, Bialer M, Arcavi L, Shachbari A, Kapitulnik J, Soback S. Genetic
polymorphism of CYP2D6 and CYP2C19 metabolism determined by
phenotyping Israeli ethnic groups. Ther Drug Monit. 2000;22(5):510–6.
27. Mikus G. Introduction to adverse drug reactions and drug-drug interaction.
Therapeutische Umschau Revue therapeutique. 2011;68(1):3–9.
28. Qumsieh RY, Ali BR, Abdulrazzaq YM, Osman O, Akawi NA, Bastaki SM.
Identification of new alleles and the determination of alleles and genotypes
frequencies at the CYP2D6 gene in Emiratis. PLoS One. 2011;6(12):e28943.
29. Lee S-Y, Sohn KM, Ryu JY, Yoon YR, Shin JG, Kim J-W. Sequence-based CYP2D6
genotyping in the Korean population. Ther Drug Monit. 2006;28(3):382–7.
30. Sakuyama K, Sasaki T, Ujiie S, Obata K, Mizugaki M, Ishikawa M,
Hiratsuka M. Functional Characterization of 17 CYP2D6 Allelic Variants
(CYP2D6. 2, 10, 14A–B, 18, 27, 36, 39, 47–51, 53–55, and 57). Drug
Metab Dispos. 2008;36(12):2460–7.
31. Friedrich DC, Genro JP, Sortica VA, Suarez-Kurtz G, de Moraes ME, Pena SD, dos
Santos ÂKR, Romano-Silva MA, Hutz MH. Distribution of CYP2D6 alleles and
phenotypes in the Brazilian population. PLoS One. 2014;9(10):e110691.
32. Rebsamen M, Desmeules J, Daali Y, Chiappe A, Diemand A, Rey C, Chabert
J, Dayer P, Hochstrasser D, Rossier M. The AmpliChip CYP450 test:
cytochrome P450 2D6 genotype assessment and phenotype prediction.
Pharmacogenomics J. 2009;9(1):34–41.
33. Menoyo A, del Rio E, Baiget M. Characterization of variant alleles of
cytochrome CYP2D6 in a Spanish population. Cell Biochem Funct. 2006;
24(5):381–5.
34. Beer B, Erb R, Pitterl F, Niederstätter H, Maroñas O, Gesteira A, Carracedo A,
Piatkov I, Oberacher H. CYP2D6 genotyping by liquid chromatography-
electrospray ionization mass spectrometry. Anal Bioanal Chem.
2011;400(8):2361–70.
35. Falzoi M, Pira L, Lazzari P, Pani L. Analysis of CYP2D6 allele frequencies and
identification of novel SNPs and sequence variations in Sardinians. ISRN
Genet. 2012;2013:1–10.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
He et al. BMC Genomics  (2016) 17:409 Page 9 of 9
